<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739320</url>
  </required_header>
  <id_info>
    <org_study_id>451</org_study_id>
    <nct_id>NCT03739320</nct_id>
  </id_info>
  <brief_title>A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma</brief_title>
  <official_title>A Prospective Observational Study on the Effect of Mepolizumab add-on Therapy on Daily Physical Activity in Patients With Severe Eosinophilic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sotiria General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sotiria General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Daily physical activity in adult patients with asthma remains overlooked. Limited evidence
      demonstrates reduced levels of daily physical activity in asthma populations but studies
      examining the potential effect of available therapies are missing. This study aims to
      investigate the overall levels of daily physical activity in patients with severe
      eosinophilic asthma and whether anti-interleukin-5 therapy with mepolizumab, on top of
      existing, maximal, and optimised asthma treatment, may improve patient's daily physical
      activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-centre, prospective, observational study of continuous patients who fulfil the
      definition of severe asthma and the criteria for mepolizumab (nucala; GSK) therapy. Patients
      have their daily physical activity recorded using triaxial accelerometry (DynaPort
      MoveMonitor; McRoberts) prior to treatment, and at 6 and 12 months of mepolizumab therapy
      (100 mg subcutaneously once every 4 weeks).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in daily moving time</measure>
    <time_frame>7 days</time_frame>
    <description>Moving time in minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in daily movement intensity</measure>
    <time_frame>7 days</time_frame>
    <description>Movement intensity in m/s^2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in daily time in moderate-to-vigorous-intensity activity</measure>
    <time_frame>7 days</time_frame>
    <description>Time in moderate-to-vigorous-intensity activity in minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in daily steps</measure>
    <time_frame>7 days</time_frame>
    <description>Step count</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Severe Eosinophilic Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepolizumab 100 MG Injection [Nucala]</intervention_name>
    <description>100 milligrams subcutaneously once every 4 weeks</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with severe asthma, already on maximal and optimised treatment who fulfil
        the criteria for mepolizumab add-on therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe asthma

          2. Criteria for mepolizumab therapy: blood eosinophils ≥150 cells/μL at screening or ≥300
             cells/μL in the past 12 months.

        Exclusion Criteria: Comorbidities limiting physical activity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marios Panagiotou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sotiria General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marios Panagiotou, MD</last_name>
    <phone>+306974238267</phone>
    <email>mpanagiotou@med.uoa.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikoletta Rovina, MD</last_name>
    <phone>+306945830212‬</phone>
    <email>nikrovina@med.uoa.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sotiria General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marios Panagiotou, MD</last_name>
      <phone>+00306974238267</phone>
      <email>mpanagiotou@med.uoa.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>November 8, 2018</last_update_submitted>
  <last_update_submitted_qc>November 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sotiria General Hospital</investigator_affiliation>
    <investigator_full_name>Marios Panagiotou</investigator_full_name>
    <investigator_title>Respiratory Physician, PhD student</investigator_title>
  </responsible_party>
  <keyword>severe asthma</keyword>
  <keyword>biologic therapy</keyword>
  <keyword>physical activity monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pulmonary Eosinophilia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

